Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 2939-2949

  Chau, Nicole G ^a   Li, Yvonne Y ^a   Jo, Vickie Y ^b   Rabinowits, Guilherme ^a   Lorch, Jochen H ^a   Tishler, Roy B ^b   Margalit, Danielle N ^b   Schoenfeld, Jonathan D ^b   Annino, Don J ^b   Goguen, Laura A ^b   Thomas, Tom ^b   Becker, Hailey ^a   Haddad, Tyler ^a   Krane, Jeffrey F ^b   Lindeman, Neal I ^b   Shapiro, Geoffrey I ^a   Haddad, Robert I ^a   Hammerman, Peter S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN; VASCULOTROPIN RECEPTOR; CCND1 PROTEIN, HUMAN; CDKN2A PROTEIN, HUMAN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2C; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MLL2 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL CYCLE REGULATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; OUTPATIENT CARE; OVERALL SURVIVAL; PATIENT CARE; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VERY ELDERLY; DISEASE FREE SURVIVAL; GENETICS; HEAD AND NECK TUMOR; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84975048476     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2314     Document Type: Article

References (32)

1. Ferlay J, Soerjomatarm I, Ervik M, Dikshit M, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: IARCCancerBase No. 11 [Internet]. 2012 v1.0. Available from: http://globocan.iarc.fr. September 4, 2015.
2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
3. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.
4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
6. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82.
7. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013;3:770-81.
8. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013;3:761-9.
9. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015;21:632-41.
10. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
11. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
12. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009;4:e7887.
13. Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 2015;26:1216-23.
14. Nichols AC, Palma DA, Chow W, Tan S, Rajakumar C, Rizzo G, et al. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2013;139:617-22.
15. Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, et al. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer 2013;13:602.
16. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 2013;5:49.
17. Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, et al. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer 2012;12:416.
18. Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, et al. Somatic copy number abnormalities and mutations in PI3K/AKT/mTOR pathway have prognostic significance for overall survival in platinum treated locally advanced or metastatic urothelial tumors. PLoS One 2015;10:e0124711.
19. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res 2013;73:6289-98.
20. Theurer JA, Stecho W, Yoo J, Kwan K, Wehrli B, Harry V, et al. Feasibility of targeting PIK3CA mutations in head and neck squamous cell carcinoma. Pathol Oncol Res 2016;22:35-40.
21. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
22. Saranath D, Chang SE, Bhoite LT, Panchal RG, Kerr IB, Mehta AR, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991;63:573-8.
23. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014;106.
24. Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, et al. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck 2014;36:1547-54.
25. Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, et al. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs 2015;26:835-42.
26. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015;21:1514-24.
27. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50.
28. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015;16:583-94.
29. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011;12:333-43.
30. Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14:697-710.
31. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-24.
32. Mullard A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov 2015;14:513-5.